Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction

Phase 4

Completed

• Conditions: Erectile Dysfunction; Erectile Dysfunction With Diabetes Mellitus
• Interventions: Drug: Tadalafil 5mg

• Registration Number: NCT05446493
• Lead Sponsor: Aswan University

Brief Summary

The aim of this current study is to estimate serum level of YKL-40, serum total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3 months.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-04-01
• Primary Completion: 2021-03-15
• Study Completion: 2022-01-05
• Study First Submitted: 2022-01-05
• Status Verified: 2022-07
• Study First Submitted QC: 2022-07-05
• Last Update Submitted: 2022-07-05
• Study First Posted: 2022-07-06
• Last Update Posted: 2022-07-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

• Diabetic patients with ED.

Exclusion Criteria

• Patients with history of pelvic trauma.
• Patients with major pelvic surgical intervention.
• Patients with hypogonadism and hyperprolactinemia.
• Patients with chronic liver disease.
• Patients with cardio vascular system diseases.
• History of chronic intake of central nervous system, anti androgen drugs or other drugs as Tramadol.
• Smokers patients.
• Patients with non-vasculogenic Erectile dysfunction.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tadalafil group	Tadalafil 5mg	Each patient will be treated by tadalafil 5mg daily for 3months

Primary Outcome Measures

Name	Time	Method
Serum YKL-40 and platelets indices in erectile dysfunction	3 months	Measurement of YKL-40 and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil.

Secondary Outcome Measures

Name	Time	Method
Effect of tadalafil on Erectile dysfucntion patients	3 months	To show the therapeutic effect of tadalafil in dose 5 mg daily on Erectile dysfucntion patients and assess their response by international index of erectile function (IIEF-5)

Trial Locations

Locations (1)

Aswan university; 🇪🇬 Aswan, Egypt